-+ 0.00%
-+ 0.00%
-+ 0.00%

BLOSSOMHILL THERAPEUTICS - TO INITIATE GLOBAL PHASE 2 STUDY FOR EGFR C797S-POSITIVE NSCLC IN Q1 2027

Reuters·09/15/2026 11:03:25

Please log in to view news